|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAPK7 |
Gene summary for MAPK7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAPK7 | Gene ID | 5598 |
| Gene name | mitogen-activated protein kinase 7 | |
| Gene Alias | BMK1 | |
| Cytomap | 17p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024QZ20 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5598 | MAPK7 | LZE4T | Human | Esophagus | ESCC | 3.03e-03 | 1.02e-01 | 0.0811 |
| 5598 | MAPK7 | LZE24T | Human | Esophagus | ESCC | 3.06e-11 | 2.33e-01 | 0.0596 |
| 5598 | MAPK7 | P1T-E | Human | Esophagus | ESCC | 2.41e-07 | 3.63e-01 | 0.0875 |
| 5598 | MAPK7 | P2T-E | Human | Esophagus | ESCC | 1.65e-10 | 1.77e-01 | 0.1177 |
| 5598 | MAPK7 | P4T-E | Human | Esophagus | ESCC | 4.11e-06 | 1.17e-01 | 0.1323 |
| 5598 | MAPK7 | P8T-E | Human | Esophagus | ESCC | 5.87e-06 | 1.49e-01 | 0.0889 |
| 5598 | MAPK7 | P9T-E | Human | Esophagus | ESCC | 7.67e-08 | 1.10e-01 | 0.1131 |
| 5598 | MAPK7 | P10T-E | Human | Esophagus | ESCC | 1.30e-15 | 2.87e-01 | 0.116 |
| 5598 | MAPK7 | P11T-E | Human | Esophagus | ESCC | 3.10e-10 | 3.96e-01 | 0.1426 |
| 5598 | MAPK7 | P12T-E | Human | Esophagus | ESCC | 8.08e-19 | 2.91e-01 | 0.1122 |
| 5598 | MAPK7 | P15T-E | Human | Esophagus | ESCC | 7.19e-09 | 1.04e-01 | 0.1149 |
| 5598 | MAPK7 | P16T-E | Human | Esophagus | ESCC | 4.12e-11 | 1.98e-01 | 0.1153 |
| 5598 | MAPK7 | P17T-E | Human | Esophagus | ESCC | 5.97e-05 | 2.65e-01 | 0.1278 |
| 5598 | MAPK7 | P20T-E | Human | Esophagus | ESCC | 6.13e-11 | 2.01e-01 | 0.1124 |
| 5598 | MAPK7 | P21T-E | Human | Esophagus | ESCC | 9.02e-11 | 2.14e-01 | 0.1617 |
| 5598 | MAPK7 | P22T-E | Human | Esophagus | ESCC | 4.41e-07 | 1.30e-01 | 0.1236 |
| 5598 | MAPK7 | P23T-E | Human | Esophagus | ESCC | 7.41e-07 | 2.09e-01 | 0.108 |
| 5598 | MAPK7 | P24T-E | Human | Esophagus | ESCC | 1.47e-03 | 1.10e-01 | 0.1287 |
| 5598 | MAPK7 | P26T-E | Human | Esophagus | ESCC | 3.62e-03 | 1.25e-01 | 0.1276 |
| 5598 | MAPK7 | P27T-E | Human | Esophagus | ESCC | 4.30e-10 | 2.04e-01 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
| GO:00607595 | Esophagus | ESCC | regulation of response to cytokine stimulus | 103/8552 | 162/18723 | 3.14e-06 | 3.53e-05 | 103 |
| GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
| GO:00380347 | Esophagus | ESCC | signal transduction in absence of ligand | 48/8552 | 65/18723 | 3.63e-06 | 3.97e-05 | 48 |
| GO:00971927 | Esophagus | ESCC | extrinsic apoptotic signaling pathway in absence of ligand | 48/8552 | 65/18723 | 3.63e-06 | 3.97e-05 | 48 |
| GO:00073698 | Esophagus | ESCC | gastrulation | 115/8552 | 185/18723 | 4.35e-06 | 4.64e-05 | 115 |
| GO:0036003110 | Esophagus | ESCC | positive regulation of transcription from RNA polymerase II promoter in response to stress | 21/8552 | 24/18723 | 2.57e-05 | 2.17e-04 | 21 |
| GO:1902175110 | Esophagus | ESCC | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 24/8552 | 29/18723 | 4.50e-05 | 3.55e-04 | 24 |
| GO:0051346110 | Esophagus | ESCC | negative regulation of hydrolase activity | 208/8552 | 379/18723 | 1.76e-04 | 1.14e-03 | 208 |
| GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
| GO:003647320 | Esophagus | ESCC | cell death in response to oxidative stress | 59/8552 | 95/18723 | 9.12e-04 | 4.65e-03 | 59 |
| GO:20012394 | Esophagus | ESCC | regulation of extrinsic apoptotic signaling pathway in absence of ligand | 30/8552 | 43/18723 | 1.21e-03 | 5.88e-03 | 30 |
| GO:190217616 | Esophagus | ESCC | negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 16/8552 | 20/18723 | 1.85e-03 | 8.40e-03 | 16 |
| GO:00714986 | Esophagus | ESCC | cellular response to fluid shear stress | 16/8552 | 21/18723 | 4.47e-03 | 1.76e-02 | 16 |
| GO:19010992 | Esophagus | ESCC | negative regulation of signal transduction in absence of ligand | 23/8552 | 33/18723 | 4.57e-03 | 1.78e-02 | 23 |
| GO:20012402 | Esophagus | ESCC | negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 23/8552 | 33/18723 | 4.57e-03 | 1.78e-02 | 23 |
| GO:190288220 | Esophagus | ESCC | regulation of response to oxidative stress | 58/8552 | 98/18723 | 4.86e-03 | 1.88e-02 | 58 |
| GO:00344054 | Esophagus | ESCC | response to fluid shear stress | 24/8552 | 35/18723 | 5.25e-03 | 1.97e-02 | 24 |
| GO:190040720 | Esophagus | ESCC | regulation of cellular response to oxidative stress | 52/8552 | 89/18723 | 1.04e-02 | 3.56e-02 | 52 |
| GO:190320120 | Esophagus | ESCC | regulation of oxidative stress-induced cell death | 44/8552 | 74/18723 | 1.18e-02 | 3.94e-02 | 44 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
| hsa0465727 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
| hsa0472225 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
| hsa05418310 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
| hsa0465734 | Esophagus | ESCC | IL-17 signaling pathway | 66/4205 | 94/8465 | 3.93e-05 | 1.75e-04 | 8.99e-05 | 66 |
| hsa04722111 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAPK7 | SNV | Missense_Mutation | c.715N>C | p.Tyr239His | p.Y239H | Q13164 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MAPK7 | SNV | Missense_Mutation | c.671N>T | p.Thr224Met | p.T224M | Q13164 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| MAPK7 | SNV | Missense_Mutation | rs748090158 | c.1502C>A | p.Ala501Asp | p.A501D | Q13164 | protein_coding | tolerated_low_confidence(0.17) | possibly_damaging(0.543) | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| MAPK7 | SNV | Missense_Mutation | rs748090158 | c.1502N>A | p.Ala501Asp | p.A501D | Q13164 | protein_coding | tolerated_low_confidence(0.17) | possibly_damaging(0.543) | TCGA-E2-A156-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| MAPK7 | SNV | Missense_Mutation | rs201284087 | c.502N>T | p.Arg168Trp | p.R168W | Q13164 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAPK7 | SNV | Missense_Mutation | c.775N>T | p.Arg259Cys | p.R259C | Q13164 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
| MAPK7 | SNV | Missense_Mutation | c.1754C>T | p.Ser585Phe | p.S585F | Q13164 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| MAPK7 | SNV | Missense_Mutation | novel | c.160N>A | p.Glu54Lys | p.E54K | Q13164 | protein_coding | tolerated(0.38) | possibly_damaging(0.845) | TCGA-MY-A913-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAPK7 | SNV | Missense_Mutation | novel | c.1819N>T | p.Pro607Ser | p.P607S | Q13164 | protein_coding | tolerated(0.44) | benign(0) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| MAPK7 | SNV | Missense_Mutation | novel | c.2129T>C | p.Val710Ala | p.V710A | Q13164 | protein_coding | deleterious(0) | benign(0.107) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | TG02, SB1317 | |||
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 328083508 | ||
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | sorafenib | SORAFENIB | 20124951 | |
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 249565744 | ||
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 381118893 | ||
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | XMD8-85 | CHEMBL1673039 | 21412406 | |
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 249565737 | ||
| 5598 | MAPK7 | ENZYME, KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, TRANSCRIPTION FACTOR | inhibitor | 328083482 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |